keyword
MENU ▼
Read by QxMD icon Read
search

ZES

keyword
https://www.readbyqxmd.com/read/29020300/impact-of-design-of-coronary-stents-and-length-of-dual-antiplatelet-therapies-on-ischaemic-and-bleeding-events-a-network-meta-analysis-of-64-randomized-controlled-trials-and-102%C3%A2-735-patients
#1
Fabrizio D'Ascenzo, Mario Iannaccone, Gaelle Saint-Hilary, Maurizio Bertaina, Stefanie Schulz-Schüpke, Cheol Wahn Lee, Alaide Chieffo, Gerard Helft, Sebastiano Gili, Umberto Barbero, Giuseppe Biondi Zoccai, Claudio Moretti, Fabrizio Ugo, Maurizio D'Amico, Roberto Garbo, Gregg Stone, Sara Rettegno, Pierluigi Omedè, Federico Conrotto, Christian Templin, Antonio Colombo, Seung-Jung Park, Adnan Kastrati, David Hildick-Smith, Mauro Gasparini, Fiorenzo Gaita
Aims: The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Methods and results: Randomized controlled trials comparing different types of DES and/or DAPT durations were selected. The primary endpoint was Major Adverse Cardiovascular Events (MACE) [a composite of death, myocardial infarction (MI), and target vessel revascularization]...
August 11, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29019150/the-zollinger-ellison-syndrome-is-there-a-role-for-somatostatin-analogues-in-the-treatment-of-the-gastrinoma
#2
REVIEW
Valentina Guarnotta, Chiara Martini, Maria Vittoria Davì, Genoveffa Pizza, Annamaria Colao, Antongiulio Faggiano
PURPOSE: Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy. METHODS: We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger-Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines...
October 10, 2017: Endocrine
https://www.readbyqxmd.com/read/28994655/functional-comparison-between-buma-supreme-biodegradable-polymer-sirolimus-eluting-and-durable-polymer-zotarolimus-eluting-coronary-stents-using-quantitative-flow-ratio-pioneer-qfr-substudy
#3
Taku Asano, Yuki Katagiri, Carlos Collet, Erhan Tenekecioglu, Yosuke Miyazaki, Yohei Sotomi, Giovanni Amoroso, Adel Aminian, Salvatore Brugaletta, Mathias Vrolix, Rosana Hernandez-Antolín, Pim van de Harst, Andres Iñiguez, Luc Janssens, Pieter Smits, Joanna J Wykrzykowska, Vasco Gama Ribeiro, Helder Periera, Pedro Canas da Silva, Jan J Piek, Johan H C Reiber, Clemens von Birgelen, Manel Sabaté, Yoshinobu Onuma, Patrick W Serruys
AIMS: Quantitative Flow Ratio (QFR) based on 3-dimensional quantitative coronary angiography (3D-QCA) is a novel method to assess the physiological functionality after treatment with stents. The current study aimed to evaluate the difference in physiological functionality 9 months after implantation of a bioresorbable polymer-based sirolimus-eluting stent with an electrografting base layer (BuMA Supreme: B-SES) versus a durable polymer-based zotarolimus-eluting stent (Resolute: R-ZES)...
October 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28949124/diagnosis-and-management-of-zollinger-ellison-syndrome-in-2017
#4
Claudio DE Angelis, Pablo Cortegoso Valdivia, Ludovica Venezia, Mauro Bruno, Rinaldo Pellicano
Zollinger-Ellison Syndrome (ZES) is a clinical syndrome characterized by gastric acid hypersecretion due to the ectopic secretion of gastrin by a gastrinoma, a neuroendocrine tumor (NET) which mostly develops in the duodenum and in the pancreas. This syndrome was first described by Zollinger and Ellison in 1964; if left untreated, ZES can lead to multiple complications mainly due to gastric hypersecretion and some patients can suffer from the complications of an advanced metastatic disease. Although its clinical features are considered typical, the diagnosis of ZES is often challenging for the clinician...
September 25, 2017: Minerva Endocrinologica
https://www.readbyqxmd.com/read/28923787/first-in-man-randomized-comparison-of-buma-supreme-biodegradable-polymer-sirolimus-eluting-versus-durable-polymer-zotarolimus-eluting-coronary-stents-the-pioneer-trial
#5
Clemens von Birgelen, Taku Asano, Giovanni Amoroso, Adel Aminian, Salvatore Brugaletta, Mathias Vrolix, Rosana Hernandez-Antolín, Pim van de Harst, Andres Iñiguez, Luc Janssens, Pieter C Smits, Joanna J Wykrzykowska, Vasco Gama Ribeiro, Helder Periera, Pedro Canas da Silva, Jan J Piek, Yoshinobu Onuma, Patrick W Serruys, Manel Sabaté
AIMS: A second iteration of a sirolimus-eluting stent (SES) that has a biodegradable PLGA-polymer coating with electrografting base layer on a thin-strut (80µm) cobalt-chromium platform (BuMA Supreme; SINOMED, Tianjin, China) has been developed. This first-in-man trial assessed the efficacy and safety of the novel device. METHODS AND RESULTS: This randomized, multi-center, single-blinded, non-inferiority trial compared BuMA Supreme SES versus contemporary durable polymer zotarolimus-eluting stents (ZES) in terms of angiographic in-stent late lumen loss (LLL) at 9-months follow-up as the primary endpoint...
September 19, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28846542/impact-of-bioresorbable-versus-permanent-polymer-on-long-term-vessel-wall-inflammation-and-healing-a-comparative-drug-eluting-stent-experimental-study
#6
Gregory J Wilson, Jennifer McGregor, Gerard Conditt, Masahiko Shibuya, Natalia Sushkova, Michael J Eppihimer, Steven P Hawley, Serge D Rousselle, Barbara A Huibregtse, Keith D Dawkins, Juan F Granada
AIMS: Drug-Eluting Stents (DES) have evolved to bioresorbable polymers as a method of drug delivery. The impact of bioresorbable polymer on long-term neointimal formation, inflammation, and healing has not been fully characterized. METHODS AND RESULTS: A comparative DES study was performed in the Familial Hypercholesterolemic Swine model of coronary stenosis. Permanent-polymer DES (zotarolimus- eluting [ZES] or everolimus- eluting [EES]) were compared to bioresorbable polymer everolimus-eluting stents (BP-EES) and BMS...
August 29, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28794001/randomized-comparison-of-ridaforolimus-and-zotarolimus-eluting-coronary-stents-in-patients-with-coronary-artery-disease-primary-results-from-the-bionics-trial-bionir-ridaforolimus-eluting-coronary-stent-system-in-coronary-stenosis
#7
RANDOMIZED CONTROLLED TRIAL
David E Kandzari, Pieter C Smits, Michael P Love, Ori Ben-Yehuda, Shmuel Banai, Simon D Robinson, Michael Jonas, Ran Kornowski, Rodrigo Bagur, Andres Iniguez, Haim Danenberg, Robert Feldman, Rajiv Jauhar, Harish Chandna, Manish Parikh, Gidon Y Perlman, Mercedes Balcells, Peter Markham, Melek Ozgu Ozan, Philippe Genereux, Elazer R Edelman, Martin B Leon, Gregg W Stone
BACKGROUND: The safety and efficacy of a novel cobalt alloy-based coronary stent with a durable elastomeric polymer eluting the antiproliferative agent ridaforolimus for treatment of patients with coronary artery disease is undetermined. METHODS: A prospective, international 1:1 randomized trial was conducted to evaluate in a noninferiority design the relative safety and efficacy of ridaforolimus-eluting stents (RESs) and slow-release zotarolimus-eluting stents among 1919 patients undergoing percutaneous coronary intervention at 76 centers...
October 3, 2017: Circulation
https://www.readbyqxmd.com/read/28776139/catching-the-zebra-clinical-pearls-and-pitfalls-for-the-successful-diagnosis-of-zollinger-ellison-syndrome
#8
REVIEW
Aaron H Mendelson, Mark Donowitz
Zollinger-Ellison syndrome (ZES) results from an ectopic gastrin-secreting tumor leading to peptic ulcer disease, reflux, and chronic diarrhea. While early recognition portends an excellent prognosis with >80% survival at 15 years, symptoms are often nonspecific making the diagnosis difficult to establish. Diagnosis involves a series of tests, including fasting gastrin, gastric pH, chromogranin A, and secretin stimulation. Performing these tests in the correct sequence and at the proper time is essential to avoid inaccurate results...
August 3, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28743907/long-term-2-5-years-adverse-clinical-outcomes-associated-with-zes-versus-ses-pes-and-ees-a-meta-analysis
#9
Pravesh Kumar Bundhun, Akash Bhurtu, Manish Pursun, Mohammad Zafooruddin Sani Soogund, Abhishek Rishikesh Teeluck, Wei-Qiang Huang
Several previously published trials comparing Zotarolimus Eluting Stents (ZES) with Sirolimus Eluting Stents (SES), Paclitaxel Eluting Stents (PES) or Everolimus Eluting Stents (EES) at a follow up period of 1 year, were continually being followed up in order to assess the long-term outcomes. In this meta-analysis, we aimed to compare the long-term (2-5 years) adverse clinical outcomes which were associated with ZES versus SES, PES and EES following Percutaneous Coronary Intervention (PCI). Risk Ratios (RR) with 95% Confidence Intervals (CIs) were generated and the analysis was carried out by the RevMan 5...
July 25, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28692458/angiographic-and-clinical-outcomes-after-recanalization-of-coronary-chronic-total-occlusions-with-the-orsiro-sirolimus-eluting-stent-compared-with-the-resolute-zotarolimus-eluting-stent
#10
Sinisa Markovic, Michael Lützner, Sergiu Dragomir, Wolfgang Rottbauer, Jochen Wöhrle
OBJECTIVE: The third generation drug eluting Orsiro stent had shown already promising results in non-complex lesions. BACKGROUND: We evaluated angiographic and 24 month clinical results of the sirolimus eluting Orsiro stents (O-SES) after recanalization of coronary chronic total occlusions (CTO). Results were compared with the zotarolimus eluting Resolute Integrity (R-ZES). METHODS: In a prospective series 57 patients were treated with a R-ZES followed by 74 patients treated with a O-SES stent...
August 2017: Coronary Artery Disease
https://www.readbyqxmd.com/read/28677608/conformational-study-of-the-3-6-dihydro-2h-1-4-oxazin-2-one-fragment-in-8-tert-butyl-7-methoxy-8-methyl-9-oxa-6-azaspiro-4-5-decane-2-10-dione-stereoisomers
#11
Ewa Żesławska, Anna Jakubowska, Wojciech Nitek
Unnatural cyclic α-amino acids play an important role in the search for biologically active compounds and macromolecules. Enantiomers of natural amino acids with a D configuration are not naturally encoded, but can be chemically synthesized. The crystal structures of two enantiomers obtained by a method of stereoselective synthesis, namely (5R,8S)-8-tert-butyl-7-methoxy-8-methyl-9-oxa-6-azaspiro[4.5]decane-2,10-dione, (1), and (5S,8R)-8-tert-butyl-7-methoxy-8-methyl-9-oxa-6-azaspiro[4.5]decane-2,10-dione, (2), both C14H21NO4, were determined by X-ray diffraction...
July 1, 2017: Acta Crystallographica. Section C, Structural Chemistry
https://www.readbyqxmd.com/read/28610782/assessment-of-treatment-response-by-colony-forming-units-time-to-culture-positivity-and-the-molecular-bacterial-load-assay-compared-in-a-mouse-tuberculosis-model
#12
Gerjo J de Knegt, Laura Dickinson, Henry Pertinez, Dimitrios Evangelopoulos, Timothy D McHugh, Irma A J M Bakker-Woudenberg, Gerry R Davies, Jurriaan E M de Steenwinkel
The aim of the study is to compare counting of colony forming units (CFU), the time to positivity (TTP) assay and the molecular bacterial load (MBL) assay, and explore whether the last assays can detect a subpopulation which is unable to grown on solid media. CFU counting, TTP and the MBL assay were used to determine the mycobacterial load in matched lung samples of a murine tuberculosis model. Mice were treated for 24 weeks with 4 treatment arms: isoniazid (H) - rifampicin (R) - pyrazinamide (Z), HRZ-Streptomycin (S), HRZ - ethambutol (E) or ZES...
July 2017: Tuberculosis
https://www.readbyqxmd.com/read/28544782/rationale-and-design-of-amphilimus-sirolimus-eluting-stents-versus-zotarolimus-eluting-stents-in-all-comers-requiring-percutaneous-coronary-intervention-recre8-a-multicenter-randomized-clinical-trial
#13
Rik Rozemeijer, Mèra Stein, Peter Frambach, Michiel Voskuil, Adriaan O Kraaijeveld, Ramón Rodríguez-Olivares, Leo Timmers, Bruno Pereira, Saskia Z Rittersma, Pierfrancesco Agostoni, Pieter A Doevendans, Pieter R Stella
BACKGROUND: Amphilimus sirolimus-eluting stents (A-SES) represent a novel elution technology in the current era of drug-eluting stents with promising results in patients with diabetes mellitus. At present no large trial has been designed to evaluate clinical outcomes of A-SES as compared to new-generation drug-eluting stents in unselected patients. Accordingly, we designed this trial to evaluate clinical noninferiority of A-SES as compared with zotarolimus-eluting stents (ZES) in a real-world, all-comers setting...
May 22, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28480650/comparison-of-drug-eluting-balloon-followed-by-bare-metal-stent-with-drug-eluting-stent-for-treatment-of-de-novo-lesions-randomized-controlled-single-center-clinical-trial
#14
In Ho Chae, Chang Hwan Yoon, Jin Joo Park, Il Young Oh, Jung Won Suh, Young Seok Cho, Tae Jin Youn, Dong Ju Choi
The combined use of a drug-eluting balloon (DEB) and a bare metal stent (BMS) for the treatment of de novo non-small vessel coronary artery diseases (CAD) remains to be evaluated. We investigated the efficacy of a sequential treatment using a DEB together with a BMS implantation in comparison to a zotarolimus-eluting stent (ZES). This study was a prospective, randomized, open-label study. We designed it to demonstrate the non-inferiority of a sequential treatment using a DEB first followed by a BMS (DEB + BMS) compared with the use of a ZES...
June 2017: Journal of Korean Medical Science
https://www.readbyqxmd.com/read/28389121/long-term-comparative-effectiveness-of-endeavor-zotarolimus-eluting-and-everolimus-eluting-stents-in-new-york
#15
Feng Qian, Ye Zhong, Edward L Hannan
BACKGROUND: Endeavor zotarolimus-eluting stents (E-ZES) and everolimus-eluting stents (EES) as second-generation stents were approved for use in percutaneous coronary interventions (PCIs) in 2008. We aimed to evaluate the long-term outcomes of E-ZES vs. EES using New York State (NYS) cardiac registries and to compare long-term effectiveness of E-ZES vs. EES in six "off-label" and two "high-risk" subgroups. METHODS: We created a longitudinal database by linking the NYS cardiac registries, the statewide hospital discharge data, the National Death Index, and the U...
August 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28321346/a-perplexing-case-of-abdominal-pain-that-led-to-the-diagnosis-of-zollinger-ellison-syndrome
#16
Adrienne Lenhart, Mona Hassan, Alireza Meighani, Omar Sadiq, Yousuf Siddiqui
Zollinger-Ellison syndrome (ZES) is a rare clinical disorder, characterized by hypersecretion of gastric acid and multiple ulcers distal to the duodenal bulb. This occurs via the release of gastrin by neuroendocrine tumors known as gastrinomas. Patients with ZES present with nonspecific GI symptoms, which often leads to a delay in diagnosis. Our patient is a 55-year-old female with chronic abdominal pain, nausea, and diarrhea. She underwent EGD, EUS, MRCP, CT scans, and cholecystectomy, which did not reveal the cause of her symptoms...
2017: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/28303630/comparison-of-5-year-outcomes-of-paclitaxel-eluting-and-endeavor-zotarolimus-eluting-stents-in-new-york
#17
Feng Qian, Ye Zhong, Edward L Hannan
OBJECTIVES: To evaluate long-term outcomes in patients undergoing either paclitaxel-eluting stents (PES) or endeavor zotarolimus-eluting stents (E-ZES) placement and to assess comparative effectiveness of PES vs. E-ZES in different "off-label" and "high-risk" patient subgroups. BACKGROUND: PES and E-ZES are frequently used in percutaneous coronary interventions (PCIs). However, the long-term comparative effectiveness of PES vs. E-ZES in real practice is unknown...
March 17, 2017: Catheterization and Cardiovascular Interventions
https://www.readbyqxmd.com/read/28302055/comparing-stent-thrombosis-associated-with-zotarolimus-eluting-stents-versus-everolimus-eluting-stents-at-1%C3%A2-year-follow-up-a-systematic-review-and-meta-analysis-of-6-randomized-controlled-trials
#18
REVIEW
Pravesh Kumar Bundhun, Chandra Mouli Yanamala, Wei-Qiang Huang
BACKGROUND: Two thousand fifteen has been a winning year for Drug Eluting Stents (DES). Increase in the number of patients with cardiovascular diseases treated by Percutaneous Coronary Intervention (PCI) has resulted to a high demand for second generation DES. This current analysis aimed to compare the different types of Stent Thrombosis (ST) associated with Zotarolimus Eluting Stents (ZES) versus Everolimus Eluting Stents (EES) at 1 year follow up. METHODS: Electronic databases were searched for studies comparing ZES with EES...
March 16, 2017: BMC Cardiovascular Disorders
https://www.readbyqxmd.com/read/28284499/the-optimal-discontinuation-of-dual-antiplatelet-therapy-in-patients-undergoing-percutaneous-coronary-intervention-with-drug-eluting-stents-a-meta-analysis-of-randomized-trials
#19
Wei Wang, Jing Liu, Jingxue Fang, Yang Liu, Tong An, Meijuan Zou, Gang Cheng
BACKGROUND: Current guidelines recommend prolonged dual antiplatelet therapy (DAPT) for patients with drug-eluting stents (DES) implantation. Nevertheless, optimal discontinuation of DAPT remains a controversy. We performed a meta-analysis of all randomized controlled trials (RCTs) that evaluate optimal discontinuation of DAPT in patients undergoing percutaneous coronary intervention (PCI) with DES. METHODS: We searched electronic databases including PubMed, Cochrane Library, EMBASE and ClinicalTrials...
May 15, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28270118/a-case-of-type-1-multiple-endocrine-neoplasia-with-esophageal-stricture-successfully-treated-with-endoscopic-balloon-dilation-and-local-steroid-injection-combined-with-surgical-resection-of-gastrinomas
#20
Hiroyuki Matsubayashi, Noboru Kawata, Naomi Kakushima, Masaki Tanaka, Kohei Takizawa, Yoshimi Kiyozumi, Yasue Horiuchi, Keiko Sasaki, Teiichi Sugiura, Katsuhiko Uesaka, Hiroyuki Ono
BACKGROUND: In type 1 multiple endocrine neoplasia (MEN1), esophageal diseases association with excessive gastrin secretion in Zollinger-Ellison syndrome (ZES) sometimes develop. Here, we reported a case of MEN1/ZES, who developed dysphagia due to reflux esophagitis with severe esophageal stricture. Treatment for his esophageal stricture and ZES was discussed. CASE PRESENTATION: A 43-year-old man with progressive dysphagia and diarrhea was referred to the teaching hospital...
March 7, 2017: BMC Gastroenterology
keyword
keyword
17621
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"